key: cord-0734244-bkpbna2n
authors: Zazzeron, Luca; Rosovsky, Rachel P.; Bittner, Edward A.; Chang, Marvin G.
title: Comparison of Published Guidelines for the Diagnosis and the Management of Vaccine-Induced Immune Thrombotic Thrombocytopenia
date: 2021-09-07
journal: Crit Care Explor
DOI: 10.1097/cce.0000000000000519
sha: 6a4eaa92eb12edb3b4bd9eec24f5f9d6a26fcf7c
doc_id: 734244
cord_uid: bkpbna2n

The development of thrombocytopenia and thrombosis after the administration of the AstraZeneca and Johnson & Johnson/Janssen vaccines has been recently described. This new condition has been called vaccine-induced immune thrombotic thrombocytopenia. The objective of this review is to summarize the clinical characteristics and therapeutic options of vaccine-induced immune thrombotic thrombocytopenia based on available published case series. Furthermore, we provide a comparison of the diagnostic pathway and treatment recommendations provided by six major medical societies. DATA SOURCES: We searched MEDLINE, PubMed, and Cochrane Central Register of Controlled Trials databases. STUDY SELECTION: We included case series and case reports on patients who developed vaccine-induced immune thrombotic thrombocytopenia. We also included guidelines for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia from major medical societies. DATA EXTRACTION: We examined baseline risk factors, symptoms, physical signs, laboratory and imaging findings, and treatment in patients with vaccine-induced immune thrombotic thrombocytopenia reported in the case series. We also analyzed the diagnostic and treatment recommendations provided by major societal guidelines on the management of vaccine-induced immune thrombotic thrombocytopenia. DATA SYNTHESIS: Patients who developed vaccine-induced immune thrombotic thrombocytopenia were more likely to be young women (age 20–50) who were given the AstraZeneca or Johnson & Johnson/Janssen 4–28 days prior to presentation. Patients showed signs, symptoms, and imaging findings consistent with cerebral venous sinus thrombosis and splanchnic thrombosis. Laboratory findings showed thrombocytopenia, low fibrinogen, and elevate d-dimer levels, while positive platelet factor 4 antibodies were always positive. Major societal guidelines recommend avoidance of heparin and platelets. Treatment with nonheparin anticoagulants and IV immunoglobulin is also recommended. CONCLUSIONS: Vaccine-induced immune thrombotic thrombocytopenia is a rare but highly morbid complication related to the administration of the AstraZeneca and Johnson & Johnson/Janssen vaccines. Clinicians should be prepared for the early identification of patients with suspicious symptoms and prompt treatment should be initiated to avoid catastrophic deterioration. Major societal guidelines provide useful recommendations for the diagnosis and management of patients with vaccine-induced immune thrombotic thrombocytopenia.

T he global pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the rapid development of vaccines with the aim to limit the spread of SARS-CoV-2 and control the disease. Clinical trials involving tens of thousands of individuals receiving COVID-19 vaccines have demonstrated few adverse events (1-3) and vaccines were rapidly deployed. As of May 11, 2021, over 1.3 billion doses of newly developed COVID-19 vaccines have been administered worldwide (4) . In the United States, three brands of vaccines are now available: the Pfizer-BioNTech, the Moderna, and the Johnson & Johnson/Janssen vaccines. In Europe, available vaccines include the Pfizer-BioNTech and the AstraZeneca vaccines. Despite the overall safe profile of these vaccines, recently, a rare condition characterized by the development of thrombotic events in women age 18-49 who were exposed to the AstraZeneca and Johnson & Johnson/Janssen vaccines has been described (5) (6) (7) (8) . This condition is called vaccine-induced immune thrombotic thrombocytopenia (VITT), vaccine-induced prothrombotic immune thrombocytopenia, and more recently as thrombosis with thrombocytopenia syndrome (TTS). From a clinical standpoint, VITT is characterized by thrombocytopenia and the presence of symptoms related to the development of thrombosis often in unusual sites such as cerebral venous sinus thrombosis (CVST) and splanchnic vein thrombosis (SVT), although other locations may be involved (9) .

Given the high morbidity associated with the development of VITT, a number of guidelines and recommendations are now available to guide identification and management of patients with this rare condition. In this article, we summarize the clinical features, risk factors, diagnostic pathway, and management of VITT based on current evidence and recommendations from six major societal guidelines (Fig. 1) . These societies include the Centers for Disease Control and Prevention (CDC) (10) , the International Society on Thrombosis and Haemostasis interim guidance (ISTH-IG) (11), the American Society of Hematology (ASH) (12) , the American College of Cardiology (ACC) (13) , the Expert Haematology Panel (EHP) from the British Society for Haematology (14) , and the American Heart Association and American Stroke Association (AHA/ ASA) (15) .

Current evidence suggests that only the ChAdOx1nCoV-19 (AstraZeneca) and the Ad26. COV2.S (Johnson & Johnson/Janssen) vaccines are associated with the development of VITT ( Table 1) . Three independent reports describe a total of 39 patients who presented with both thrombocytopenia and thrombosis after receiving the AstraZeneca vaccine (5) (6) (7) . One case of thrombocytopenia and diffuse intravascular coagulation after the Johnson & Johnson/ Janssen vaccine has also been reported (8) .

In addition to cases published in scientific journals, as of April 4, 2021, a total of 169 cases of CVST and 53 cases of SVT out of 34 million people vaccinated with the ChAdOx1nCoV-19 (AstraZeneca) vaccine were reported to the European Medicines Agency. According to the Vaccine Adverse Event Reporting System (VAERS), as of April 12, 2021 , there were six cases of CVST with thrombocytopenia among 6.86 million people who received the Johnson &Johnson/Janssen vaccine in the United States. Additionally, the Clinical Immunization Safety Assessment (CISA) project that includes seven medical research centers in the United States identified 15 cases of TTS in people receiving the Johnson & Johnson/Janssen vaccine. No reports were submitted to VAERS among the 97.9 million people who received the Pfizer-BioNTech vaccine. Three cases of CVST out of 84.7 million Moderna vaccines were reported to VAERS, but all presented without thrombocytopenia, thus excluding a diagnosis of VITT (10).

The main difference between the AstraZeneca and the Johnson & Johnson/Janssen vaccines and other vaccines is that the former vaccines are nonreplicating adenovirus vector-based DNA vaccines (chimpanzee [ChAdOx1] and human [Ad26.COV2.S], respectively), while other vaccines such as the Pfizer-BioNTech and Moderna vaccines are messenger RNA-based vaccines. The fact that VITT has been observed only after administration of adenoviral-based vaccines suggests that adenovirus vectors may be implicated in the pathogenesis of VITT, which is characterized by the development of platelet factor 4 (PF4) antibodies, platelet activation, and thrombosis. Of note, thrombocytopenia without thrombosis has also been reported after the administration of Pfizer-BioNTech and Moderna vaccines, but these cases (n = 20) do not meet criteria for VITT diagnosis (16) and rather represent cases of immune thrombocytopenic purpura (ITP).

The main demographic and clinical characteristics of patients who have developed VITT and been reported in case series are summarized in Table 1 . The majority of patients with VITT were females with a median age of 40 years. Overall, patients were generally healthy with no major preexisting medical conditions. One patient had confirmed von Willebrand disease, anticardiolipin antibodies, and factor V Leiden; one had a history of deep vein thrombosis (DVT); and one was on combined oral contraceptive pills. None of the patients had a history of heparin-induced thrombocytopenia (HIT). These findings suggest that preexisting medical conditions do not predispose an individual to developing VITT.

Existing evidence suggests that current or prior exposure to SARS-CoV-2 is not a risk factor for developing VITT. In two reports (7, 8) , all patients with VITT (n = 24) underwent SARS-CoV-2 polymerase chain reaction testing with negative results. In the CISA project (10), 10 patients out of 15 were tested for SARS-CoV-2 on presentation with negative results. Four patients also underwent SARS-CoV-2 serologic testing and resulted negative. In the study by Scully et al (7), 10 patients underwent serologic testing for antibodies against the SARS-CoV-2 nucleocapsid protein and resulted negative. These findings suggest that VITT is not associated with concurrent or recent infection with SARS-CoV-2.

The common presenting physical signs in patients with VITT are linked to the presence of thrombocytopenia and thrombosis in some vascular beds. Petechiae and bruising are common findings on physical examination. The presence of headache, altered mental status, and focal neurologic deficits suggest CNS involvement with thrombosis of venous sinuses and possible cerebral ischemia or hemorrhage, while abdominal pain at presentation suggests thrombosis of the splanchnic veins. The pulmonary circulation is another location in which thrombosis has been described, in which patients presented with shortness of breath and chest pain. Other less common symptoms on presentation were fever, chills, and back pain.

Mild to moderate thrombocytopenia is the main laboratory feature, and its presence is required for the diagnosis of VITT. Elevated d-dimer and low fibrinogen levels are also common. Based on reported cases (Table 1) , approximately 70% of patients had positive imaging for CVST, while about 20% of patients were found with SVT. Other locations of thrombosis such as pulmonary embolism (PE) were also present but less common. While hemorrhagic features at presentation were observed only in three patients (8%), more patients showed secondary hemorrhagic conversion of the cerebral venous thrombosis. Schultz et al (5) described one patient with cerebellar hemorrhage, while three more patients showed hemorrhagic conversion of the CVST. Greinacher et al (6) reported one patient who presented with fatal intracranial hemorrhage without any specification about the location of the hemorrhage. In the report by Scully et al (7), some patients showed cerebral hemorrhage secondary to cerebral venous thrombosis. Bersinger et al (17) described one patient who presented with left frontoparietal venous hemorrhagic infarction. Table 3 shows the major societal considerations regarding diagnosis of VITT. According to existing guidelines, an urgent complete blood count and appropriate imaging tests to confirm thrombocytopenia and thromboembolism should be performed. Based on the symptoms at presentation, a CT venogram of the head should be obtained in patients presenting with headache or neurologic signs, a CT venogram of the abdomen should be obtained in patients presenting with abdominal pain, and a CT angiogram of the chest should be obtained in patients presenting with respiratory symptoms. If the platelet count is normal or imaging studies do not reveal thrombosis, VITT can be excluded, as both criteria are required for the diagnosis. Isolated thrombocytopenia might be found and more likely represents an ITP that has also been described after vaccination with Pfizer-BioNTech and Moderna vaccines (16) . If thrombocytopenia and thrombosis are confirmed, additional laboratory studies should be obtained to confirm the diagnosis of VITT. These tests include d-dimer, prothrombin time, 

Recommendations from major societal guidelines differ somewhat in their format and the details provided for management of patients with suspect or confirmed VITT ( Table 4) . While there are some major Aspirin should be continued if part of the patient's routine medication regimen, but it is not recommended to start aspirin before or after vaccination given that inhibition of thromboxane does not block platelet activation in HIT, there is an associated risk of bleeding, and the incidence of VITT is rare International Society for Thrombosis and Haemostasis's interim guidance

Do not wait for results if diagnosis of VITT seems likely Consider steroids (e.g., prednisone 1 to 2 mg/ kg) if platelet count is less than 50 × 10 9 /L Give IVIG immediately (0.5-1 g/kg daily for 2 d) Avoid platelet transfusions (unless patient requires urgent surgery), heparin, low-molecular-weight heparin, and vitamin K antagonists Consider early plasma exchange or fibrinogen substitution to > 1.0 g/L if platelet count remains less than 30 × 10 9 /L despite IVIG and steroid treatment or fibrinogen level is less than 1 g/L Give a nonheparin anticoagulant such as fondaparinux, argatroban, or a DOAC (e.g., apixaban, rivaroxaban) if platelet count is over 50 × 10 9 /L and there is no serious bleeding

Consult an expert in thrombosis, such as hematology or vascular medicine recommendations on which they all societies agree, some other recommendations are mentioned only in some of the guidelines. Major societies guidelines recommend that patients with confirmed thrombocytopenia and acute thrombosis should be admitted to the hospital, and if VITT is confirmed, patients should be transferred to a tertiary care center. If CVST is suspected or confirmed, transfer to a center with a neurosurgical expertise is strongly encouraged. The ISTH-IG, the ACC, and the AHA/ASA recommend that a hematologist or other thrombosis expert should be consulted to guide treatment and that in the presence of CVST or SVT, neurosurgical and vascular consultations should also be obtained to determine whether surgical intervention is indicated. All of the societies recommend avoiding heparin products until VITT is excluded. Based on the evidence reported by the recently published case series and the similarities of VITT to HIT, the ISTH-IG, the ASH, and the AHA/ASA recommend avoiding platelet transfusion unless patients are experiencing life-threatening bleeding or need for urgent surgery. Given the thrombotic nature of the disease and the similarities with HIT, all societies recommend administration of nonheparin anticoagulants. These nonheparin anticoagulants include fondaparinux, direct thrombin inhibitors such as argatroban or bivalirudin, or direct oral anticoagulants such as apixaban or rivaroxaban. Argatroban at a dose of 0.5 to 2.2 µg/ kg/min has been successfully employed in a patient with life-threatening extensive thrombosis in the cerebral and splanchnic veins as well as PE and DVT (17) . Bleeding and thrombotic risk should be carefully balanced and the EHP recommends that low-dose fondaparinux or critical illness dosing of argatroban may be appropriate while the platelet count is less than 30 × 10 9 /L. Based on all guidelines, high-dose IV immunoglobulin (IVIG) should also be administered irrespective of the degree of thrombocytopenia (e.g., 1 g/ kg for 2 d). Given the rapidly evolving nature of this condition and the high rates of morbidity and mortality, if the clinical suspicion for VITT is high, IVIG treatment should be started promptly while awaiting confirmatory diagnosis with PF4 antibody testing, as based on the guidelines available, this intervention may positively affect clinical outcomes, although data to support this are still lacking. Other recommendations found in major societal guidelines regard treatment with steroids. Whether steroids improve outcome is unknown; however, the ISTH-IG, the EHP, and the AHA/ASA recommend consideration of steroid treatment (e.g., prednisone 1 to 2 mg/kg) since the benefit likely outweighs risks of harm. The same societies (the ISTH-IG, the EHP, and the AHA/ASA) also recommend replacement of fibrinogen to ensure a level above 1 g/L using fibrinogen concentrate or cryoprecipitate.

Although there are no reports available on the efficacy of plasma exchange for the treatment of VITT, the ISTH-IG and the EHP guidelines suggest that in resistant disease in which platelet count remains low and there is continuous thrombosis despite IVIG and steroid treatment, plasma exchange should be considered. For patients who are refractory to repeat administration of IVIG and plasma exchange, the EHP suggests the use of rituximab, although there is no evidence of its efficacy in VITT at present.

None of the major societal guidelines recommend aspirin as treatment or prophylaxis for VITT. The CDC, ASH, and ACC recommend against the use of aspirin as treatment and/or prophylaxis for VITT given a lack of evidence including that its inhibition of thromboxane does not block platelet activation in HIT, an increased risk of bleeding, and the rare occurrence rate of VITT. The CDC recommends that aspirin should be continued if already part of the patient's routine medical regimen.

Finally, since VITT represents a serious and lifethreatening adverse event following receipt of certain COVID-19 vaccines, it should be reported to VAERS that is required by the Food and Drug Administration (FDA) and its rules on the Emergency Use Authorizations for COVID-19 vaccines.

Although clinicians are now provided with basic tools for the identification and management of patients at risk of VITT, there are still many questions that need to be answered.

First, the pathophysiological mechanisms underlying the development of VITT with positive PF4 antibodies in the absence of prior heparin exposure have not been fully elucidated. The reason why adenoviral vaccines and not messenger RNA (mRNA) vaccines are associated with VITT also needs explanation. Additionally, the prevalence of positive PF4 antibodies in patients who underwent vaccination and who did not develop thrombosis or thrombocytopenia is unknown; therefore, the relationship between the pathogenesis of VITT and the presence of PF4 antibodies deserves further study. Further research on these topics will help with the selection of vaccine for a given patient and potentially the development of safer vaccines.

A second important question is whether the incidence of VITT in patients' post-vaccination with AstraZeneca or Johnson & Johnson/Janssen vaccines is higher than in the general population. The existing reporting systems adopted by the FDA and the European Medicines Agencies to identify vaccine-related adverse effects may overemphasize the relevance of rare conditions that would otherwise be unnoticed in the general population.

A third unanswered question is whether the risk of developing complications such as CVST, SVT, or PE after vaccination is higher than the risk of developing similar complications in COVID-19 disease. Reports of vaccine-associated side effects such as CVST and VITT may induce fear of vaccination in the general population. However, coagulopathy and thrombophilia have often been reported during SARS-CoV-2 infection and the risk of developing CVST with COVID-19 has been shown to be higher than in subjects receiving mRNA vaccines (18) . Further studies to comparing the incidence of thrombotic complications in patients with COVID-19 and in patients who received adenoviral vaccines will be required.

In summary, VITT is a rare but highly morbid complication related to the administration of the AstraZeneca and Johnson & Johnson/Janssen vaccines. Clinicians should be prepared for the early identification of patients with suspicious symptoms and prompt treatment should be initiated to avoid catastrophic deterioration. Major societal guidelines provide useful recommendations for the diagnosis and management of patients with VITT. Clinicians should remain updated on emerging literature to optimize the care of patients presenting with suspected VITT.

C4591001 Clinical Trial Group: Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

COVE Study Group: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

The New York Times: Tracking Coronavirus Vaccinations Around the World. Accessed

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

SAR-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Centers for Disease Control and Prevention: Johnson & Johnson/Janssen COVID-19 Vaccine and Thrombosis With Thrombocytopenia Syndrome (TTS): Update for Clinicians. 2021. Available at

Thrombosis With Thrombocy topenia Syndrome (Also Termed Vaccine-Induced Thrombotic Thrombocytopenia). 2021. Available at

American College of Cardiology: Vaccine-Induced Thrombotic Thrombocytopenia (VITT) and COVID-19 Vaccines: What Cardiovascular Clinicians Need to Know. Cardiology Magazine

British Society for Haematology: Guidance Produced by the Expert Haematology Panel (EHP) Focused on Vaccine Induced Thrombosis and Thrombocytopenia (VITT). 2021. Available at

On Behalf of the American Heart Association/American Stroke Association Stroke Council Leadership: Diagnosis and management of cerebral venous sinus thrombosis with vaccineinduced thrombotic thrombocytopenia

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Using nonheparin anticoagulant to treat a near-fatal case with multiple venous thrombotic lesions during ChAdOx1 nCoV-19 vaccinationrelated vaccine-induced immune thrombotic thrombocytopenia

Cerebral venous thrombosis: A retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine

All authors wrote and reviewed the article.The authors have disclosed that they do not have any potential conflicts of interest.For information regarding this article, E-mail: mgchang@partners. org; rprosovsky@partners.org